Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Interpace Biosciences, Inc. (IDXG) had Consolidated Net Income/Loss of $-0.64M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$9.23M |
|
$-0.64M |
|
$3.96M |
|
$5.28M |
|
$9.70M |
|
$-0.47M |
|
$-0.07M |
|
$-0.53M |
|
$-0.53M |
|
$-0.53M |
|
$-0.53M |
|
|
Consolidated Net Income/Loss |
$-0.64M |
$-0.53M |
|
$-0.47M |
|
$-0.25M |
|
4.42M |
|
4.42M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$9.50M |
|
$1.37M |
|
$2.83M |
|
$12.34M |
|
$7.15M |
|
-- |
|
$6.40M |
|
$13.55M |
|
$-1.21M |
|
$-1.21M |
|
$-1.21M |
|
4.42M |
|
| Cash Flow Statement Financials | |
$1.75M |
|
$-0.20M |
|
$-2.51M |
|
$1.46M |
|
$0.50M |
|
$-0.96M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.33 |
|
-- |
|
-- |
|
-- |
|
-1.46 |
|
57.15% |
|
-5.07% |
|
-5.07% |
|
-- |
|
-5.77% |
|
-6.93% |
|
$1.55M |
|
-- |
|
-- |
|
-- |
|
0.75 |
|
-- |
|
1.28 |
|
70.49 |
|
43.94% |
|
43.94% |
|
-4.32% |
|
43.94% |
|
$-0.27 |
|
$0.35 |
|
$0.40 |
|